Genesis Therapeutics
Indrawan McAlpine has extensive work experience in the pharmaceutical industry. Indrawan began their career as a Research Associate at Merck in 1991 and worked there until 1993. In 2000, McAlpine joined Pfizer as a Principal Scientist/Research Scientist and later progressed to the roles of Senior Principal Scientist, Associate Research Fellow, and Research Fellow. Indrawan worked at Pfizer until January 2023 when they joined Genesis Therapeutics as the Vice President of Chemistry. Indrawan McAlpine's expertise and knowledge in chemistry make him a valuable asset in the industry.
Indrawan McAlpine has completed a Bachelor of Science degree in Chemistry from the University of Illinois Urbana-Champaign, which was obtained from 1987 to 1991. Afterwards, McAlpine pursued further education and obtained a Ph.D. in Chemistry from UCLA, attending from 1993 to 1998. Following this, McAlpine engaged in postdoctoral study at Harvard University from 1998 to 2000, focusing on Chemistry.
This person is not in any offices
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.